TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21521847

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU daily for 96 weeks)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg daily for 96 weeks)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (for 96 weeks)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 19892091

Group type: EXPERIMENTAL
Intervention: Immediate commencement of exercises within 2 hours after surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group commencing exercises on the first postoperative day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immediate commencement of exercises
Number of subjects: 30
Study: 16977654

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 U once weekly for < or = 16 weeks)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Epoetin alfa (delayed treatment until hemoglobin < 9 g/dL)
Number of subjects: 269
Study: 15807201

Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High fat breakfast
Number of subjects: 20
Study: 10917932

Group type: EXPERIMENTAL
Intervention: Procyanidin-rich chocolate (5.3 mg total procyanidin/g, 1.3 mg/g (‐)‐epicatechin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procyanidin-rich chocolate
Number of subjects: 0
Study: 9062608

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.5% end-tidal concentration for 10 min (Group Iso-10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.5% end-tidal concentration for 30 min (Group Iso-30)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen for 10 min (Group N2O)
Number of subjects: 45
Study: 8399641

Group type: EXPERIMENTAL
Intervention: Low calcium concentration dialysate (1.00 mM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard calcium concentration dialysate (1.75 mM)
Number of subjects: 18
Study: 3743529

Group type: EXPERIMENTAL
Intervention: Running program (3 sessions of 30 minutes per week for 12 weeks)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Running program (for boys)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Running program (for girls)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Regular physical education program
Number of subjects: 154
Study: 28430945

Group type: EXPERIMENTAL
Intervention: Counselling intervention
Number of subjects: 746

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 746
Study: 28404091

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (25 mg)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (300 mg)
Number of subjects: 873
Study: 24385121

Group type: EXPERIMENTAL
Intervention: 5-aminolevulonic acid (ALA) photodynamic therapy (PDT), two treatments, 2 weeks apart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group observed without treatment
Number of subjects: 0
Study: 22910239

Group type: EXPERIMENTAL
Intervention: Cranberry juice with high concentrations of proanthocyanidin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cranberry juice with no proanthocyanidin (placebo)
Number of subjects: 40
Study: 20633186

Group type: EXPERIMENTAL
Intervention: Targeted biopsies from macroscopic lesions
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-targeted biopsies from the lesser curvature
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-targeted biopsies from the antrum, angulus, and lesser curvature of the corpus
Number of subjects: 112
Study: 18950301

Group type: EXPERIMENTAL
Intervention: Blended sensor (BS)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Accelerometer (XL)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Both groups (BS and XL)
Number of subjects: 547
Study: 16012762

Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 12873814

Group type: EXPERIMENTAL
Intervention: Spironolactone and furosemide (Group 1: 50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spironolactone alone (Group 2: 50 patients)
Number of subjects: 100
Study: 10673292

Group type: EXPERIMENTAL
Intervention: Gluten free diet including oats
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional gluten free diet
Number of subjects: 92
Study: 9397291

Group type: EXPERIMENTAL
Intervention: Calcium antagonist treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study: 8394193

Group type: EXPERIMENTAL
Intervention: felodipine-ER (5 to 20 mg once daily)
Number of subjects: 20
Study: 3720571

Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g/day)
Number of subjects: 3806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3806
Study: 31882288

Group type: EXPERIMENTAL
Intervention: Cotton‐tipped applicator test with 3 strokes at differing frequencies (10, 30, or 100 seconds)
Number of subjects: 36
Study: 30767613

Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Weight shifting and gait training (WS&GT)
Number of subjects: 34
Study: 28223274

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 26604731

Group type: EXPERIMENTAL
Intervention: Erdosteine (ER) 900 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 23406466

Group type: EXPERIMENTAL
Intervention: Tailored Interactive Health Communication Application (IHCA)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Standard website (control)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Tailored IHCA
Number of subjects: 414
Study: 21870121

Group type: EXPERIMENTAL
Intervention: 2 g ALC twice a day for 90 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 61
Study: 18644845

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 52

Group type: COMPARATOR
Intervention: Endotracheal tubes
Number of subjects: 52
Study: 16841184

Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 23
Study: 12897593

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10971236

Group type: EXPERIMENTAL
Intervention: Mesalazine foam enema (2 g per day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 111
Study: 8649559

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study: 1799929

Group type: EXPERIMENTAL
Intervention: Bisoprolol (various doses)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Enalapril and hydrochlorothiazide combination
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nifedipine (new galenic form)
Number of subjects: 56
Study: 6381336

Group type: EXPERIMENTAL
Intervention: Chlorimipramine (50 mg/day) + L-5-HTP (300 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chlorimipramine + L-5-HTP
Number of subjects: 26
Study: 30587415

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation (CPVI) + ablation of electrogram dispersion areas (group A)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Stepwise ablation strategy (group B)
Number of subjects: 142
Study: 30292278

Group type: EXPERIMENTAL
Intervention: Single extracorporeal shock-wave lithotripsy (ESWL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Computed tomography texture analysis (CTTA) metrics
Number of subjects: 100
Study: 25650318

Group type: EXPERIMENTAL
Intervention: 0.1g ketoprofen
Number of subjects: 169

Group type: COMPARATOR
Intervention: 2.5g metamizole
Number of subjects: 169
Study: 24850877

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 9
Study: 21452042

Group type: EXPERIMENTAL
Intervention: MAGE-3 mRNA expression in metastatic HCC patients
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MAGE-4 mRNA expression in metastatic HCC patients
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MAGE-3 mRNA expression in localized HCC patients
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MAGE-4 mRNA expression in localized HCC patients
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: At least one type of mRNA in metastatic HCC patients
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: At least one type of mRNA in localized HCC patients
Number of subjects: 160

Group type: COMPARATOR
Intervention: MAGE-4 mRNA expression in controls and cirrhotic patients
Number of subjects: 160
Study: 19682769

Group type: EXPERIMENTAL
Intervention: Topical bexarotene 1% gel applied twice daily for 6 months
Number of subjects: 42
Study: 17577801

Group type: EXPERIMENTAL
Intervention: Bupropion (BUP) with standard cognitive-behavioral smoking cessation treatment (ST)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBTD) with BUP
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBTD) with placebo (PLAC)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Standard treatment (ST) plus placebo (PLAC)
Number of subjects: 524
Study: 15223711

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Overall (PCI and Fibrinolysis)
Number of subjects: 1572
Study: 12437794

Group type: EXPERIMENTAL
Intervention: Psycho‐educational group (PEG) intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Routine Primary Care (RPC)
Number of subjects: 45
Study: 9650013

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg t.i.d. and sodium selenite (Se) 500 micrograms per day for 24 weeks (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (group B, untreated for first 12 weeks)
Number of subjects: 24
Study: 8895036

Group type: EXPERIMENTAL
Intervention: Low sodium intake (10 mmol/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High sodium intake (350 mmol/day)
Number of subjects: 14
Study: 2181158

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 213
Study: 6103443

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrochemical sensor for estimating arterial oxygen (PaO2) and carbon dioxide (PaCO2) tensions
Number of subjects: 0
Study: 31248346

Group type: EXPERIMENTAL
Intervention: High suicide risk vignette
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Low suicide risk vignette
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Perceived behavioral control
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Subjective norms
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Attitudes
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Interaction between risk severity and perceived behavioral control
Number of subjects: 420
Study: 30617431

Group type: EXPERIMENTAL
Intervention: Life review therapy combined with memory specificity training (LRT-MST)
Number of subjects: 20
Study: 28065679

Group type: EXPERIMENTAL
Intervention: BDP/FF DPI 200/12 μg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: BDP/FF DPI 800/48 μg
Number of subjects: 49

Group type: COMPARATOR
Intervention: BDP/FF pMDI 200/12 μg
Number of subjects: 49

Group type: COMPARATOR
Intervention: BDP/FF pMDI 800/48 μg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 26398281

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 24798675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 21507074

Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) at 36 kHz for 5 min, dosage from 1.57 to 3.50 W/cm(2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 20118830

Group type: EXPERIMENTAL
Intervention: 2-session motivational interviewing plus skills-building intervention (integrated intervention; n = 48)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 2-session skills-building only comparison intervention (n = 31)
Number of subjects: 79
Study: 17628185

Group type: EXPERIMENTAL
Intervention: Vitamin E (various forms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E analogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E-based compounds
Number of subjects: 0
Study: 15530579

Group type: EXPERIMENTAL
Intervention: Patient self-report
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Doctor assessment
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Nurse assessment
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Urine isoniazid levels
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Computerized pill bottles
Number of subjects: 173
Study: 12200244

Group type: EXPERIMENTAL
Intervention: Cardiologist-controlled radiation exposure
Number of subjects: 368

Group type: COMPARATOR
Intervention: Radiographer-controlled radiation exposure
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Consultant cardiologists
Number of subjects: 368

Group type: COMPARATOR
Intervention: Registrars
Number of subjects: 368
Study: 9865556

Group type: EXPERIMENTAL
Intervention: Teflon stent
Number of subjects: 42

Group type: COMPARATOR
Intervention: Polyethylene stent
Number of subjects: 42
Study: 8536155

Group type: EXPERIMENTAL
Intervention: RISCC scoring system
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: FRR scoring system
Number of subjects: 622
Study: 2195580

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg in decaffeinated coffee)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 402926

Group type: EXPERIMENTAL
Intervention: Fluorimetric assay of minocycline in plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional large plate agar diffusion microbiological assay
Number of subjects: 0
Study: 30385098

Group type: EXPERIMENTAL
Intervention: Education Booklet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verbal Education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison between Booklet and Verbal Education
Number of subjects: 60
Study: 28657933

Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning (MAC)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (RIC)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative conditioning (NMC)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Glucocorticoid low dose (≤9 mg·kg prednisone)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Glucocorticoid high dose (>9 mg·kg prednisone)
Number of subjects: 113
Study: 25998068

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 43

Group type: COMPARATOR
Intervention: Atrial pacing
Number of subjects: 43

Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 43
Study: 24461664

Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg once a week for up to 24 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (once a week for up to 24 months)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 21723353

Group type: EXPERIMENTAL
Intervention: IXIARO(®) high titer sera (PRNT(50) titer ∼200)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: JE‐VAX(®) high titer sera (PRNT(50) titer ∼55)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-immune serum groups
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IXIARO(®) sera with titer ≥10
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Different doses of IXIARO
Number of subjects: 10
Study: 19317104

Group type: EXPERIMENTAL
Intervention: Tiotropium (Spiriva)
Number of subjects: 5993
Study: 16434206

Group type: EXPERIMENTAL
Intervention: Active warming with a forced-air warming device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warm mattresses and cotton blankets (Control)
Number of subjects: 40
Study: 15631874

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (17.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day, 5 days weekly for 6 months, 3 days weekly at month 7 and 1 day/week at month 8)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both nicotine and fluoxetine
Number of subjects: 12
Study: 11334145

Group type: EXPERIMENTAL
Intervention: LR‐3280 (doses from 1 to 24 mg) administered into target vessel through a guiding catheter
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 78
Study: 9327151

Group type: EXPERIMENTAL
Intervention: Doxorubicin 10 mg/m2 every 2 weeks with bleomycin 10 U/m2 and vincristine 1.4 mg/m2, zidovudine 100 mg five times daily, and rhGM-CSF 5 micrograms/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rhGM-CSF at doses of 2.5 to 5 micrograms/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Doxorubicin 20 mg/m2
Number of subjects: 20
Study: 9113010

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation (EBD)
Number of subjects: 202
Study: 2576359

Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theophylline (7 mg/kg b.w.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride (10 mg) and Theophylline (7 mg/kg b.w.) combined
Number of subjects: 12
Study: 1105483

Group type: EXPERIMENTAL
Intervention: Prazosin 5 mg three or four times a day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prazosin in combination with polythiazide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prazosin alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 20
Study: 30896368

Group type: EXPERIMENTAL
Intervention: Region closest to the railyard
Number of subjects: 965

Group type: COMPARATOR
Intervention: Region furthest from the railyard
Number of subjects: 965
Study: 27779571

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 119
Study: 25692717

Group type: EXPERIMENTAL
Intervention: Rhetorical question (RQ) intervention
Number of subjects: 445

Group type: COMPARATOR
Intervention: One-sided message
Number of subjects: 445

Group type: COMPARATOR
Intervention: Two-sided message
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 445
Study: 23507121

Group type: EXPERIMENTAL
Intervention: Chest tube removal on full inspiration
Number of subjects: 342

Group type: COMPARATOR
Intervention: Chest tube removal on full expiration
Number of subjects: 342
Study: 21795888

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) during wound debridement for 6 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard of care pharmacologies during wound debridement for 6 minutes
Number of subjects: 12
Study: 19424085

Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/day for 4 weeks then 16 mg/day for another 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16450235

Group type: EXPERIMENTAL
Intervention: Interactive web-based curriculum on EBM
Number of subjects: 238

Group type: COMPARATOR
Intervention: Traditional clerkship experience
Number of subjects: 238
Study: 15069728

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES) before plastic stent (PS) placement
Number of subjects: 172

Group type: COMPARATOR
Intervention: Plastic stent (PS) placement without endoscopic sphincterotomy (ES)
Number of subjects: 172
Study: 11760917

Group type: EXPERIMENTAL
Intervention: Mediation group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard procedure group
Number of subjects: 48
Study: 9230143

Group type: EXPERIMENTAL
Intervention: Controlled-release niacin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Regular niacin
Number of subjects: 29
Study: 8477561

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg/day for 5 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 2457403

Group type: EXPERIMENTAL
Intervention: Bumetanide 1 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31280757

Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 343

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 343
Study: 31434935

Group type: EXPERIMENTAL
Intervention: B. coagulans Unique IS2 (2 billion CFU)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 136
Study: 28468642

Group type: EXPERIMENTAL
Intervention: Short cognitive behavioural therapy (CBT)-based treatment by mental health nurse practitioners (MHNPs) in addition to usual GP care
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Short cognitive behavioural therapy (CBT)-based treatment by MHNPs
Number of subjects: 212
Study: 25469669

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 89

Group type: COMPARATOR
Intervention: 37% phosphoric acid etch (ETCH)
Number of subjects: 89
Study: 23426618

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 15
Study: 21978713

Group type: EXPERIMENTAL
Intervention: Oral desensitisation with cow's milk
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral desensitisation with hen's egg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral desensitisation with cow's milk and hen's egg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral desensitisation with raw hen's egg
Number of subjects: 4
Study: 18194401

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 314
Study: 16612399

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of antioxidant compounds, such as acetylcysteine and ascorbic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vasodilators and diuretics
Number of subjects: 0